THOUSAND OAKS, Calif.,
July 28, 2015 /PRNewswire/ -- Amgen
(NASDAQ:AMGN) announced that its Board of Directors today declared
a $0.79 per share dividend for the
third quarter of 2015. The dividend will be paid on Sept. 8, 2015, to all stockholders of record as
of the close of business on Aug. 17,
2015.
About Amgen
Amgen is committed to unlocking the potential of biology for
patients suffering from serious illnesses by discovering,
developing, manufacturing and delivering innovative human
therapeutics. This approach begins by using tools like advanced
human genetics to unravel the complexities of disease and
understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages
its biologics manufacturing expertise to strive for solutions that
improve health outcomes and dramatically improve people's lives. A
biotechnology pioneer since 1980, Amgen has grown to be one of the
world's leading independent biotechnology companies, has reached
millions of patients around the world and is developing a pipeline
of medicines with breakaway potential.
For more information, visit www.amgen.com and follow us on
www.twitter.com/amgen.
Forward-Looking Statements
This news release contains forward-looking statements that involve
significant risks and uncertainties, including those discussed
below and others that can be found in our Form 10-K for the year
ended Dec. 31, 2014, and in any
subsequent periodic reports on Form 10-Q and Form 8-K. Amgen is
providing this information as of the date of this news release and
does not undertake any obligation to update any forward-looking
statements contained in this document as a result of new
information, future events or otherwise.
No forward-looking statement can be guaranteed and actual
results may differ materially from those we project. The Company's
results may be affected by our ability to successfully market both
new and existing products domestically and internationally,
clinical and regulatory developments (domestic or foreign)
involving current and future products, sales growth of recently
launched products, competition from other products (domestic or
foreign) and difficulties or delays in manufacturing our products.
In addition, sales of our products are affected by reimbursement
policies imposed by third-party payers, including governments,
private insurance plans and managed care providers and may be
affected by regulatory, clinical and guideline developments and
domestic and international trends toward managed care and
healthcare cost containment as well as U.S. legislation affecting
pharmaceutical pricing and reimbursement. Government and others'
regulations and reimbursement policies may affect the development,
usage and pricing of our products. Furthermore, our research,
testing, pricing, marketing and other operations are subject to
extensive regulation by domestic and foreign government regulatory
authorities. We or others could identify safety, side effects or
manufacturing problems with our products after they are on the
market. Our business may be impacted by government investigations,
litigation and product liability claims. If we fail to meet the
compliance obligations in the corporate integrity agreement between
us and the U.S. government, we could become subject to significant
sanctions. Further, while we routinely obtain patents for our
products and technology, the protection offered by our patents and
patent applications may be challenged, invalidated or circumvented
by our competitors. We depend on third parties for a significant
portion of our manufacturing capacity for the supply of certain of
our current and future products and limits on supply may constrain
sales of certain of our current products and product candidate
development. In addition, we compete with other companies with
respect to some of our marketed products as well as for the
discovery and development of new products. Discovery or
identification of new product candidates cannot be guaranteed and
movement from concept to product is uncertain; consequently, there
can be no guarantee that any particular product candidate will be
successful and become a commercial product. Further, some raw
materials, medical devices and component parts for our products are
supplied by sole third-party suppliers. Our efforts to integrate
the operations of companies we have acquired may not be successful.
We may experience difficulties, delays or unexpected costs and not
achieve anticipated benefits and savings from our recently
announced restructuring plan. Our business performance could affect
or limit the ability of the Amgen Inc. Board of Directors to
declare a dividend or our ability to pay a dividend or repurchase
our common stock.
CONTACT: Amgen, Thousand
Oaks
Kristen Davis, 805-447-3008
(media)
Arvind Sood, 805-447-1060
(investors)
Logo -
http://photos.prnewswire.com/prnh/20081015/AMGENLOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/amgen-announces-2015-third-quarter-dividend-300120126.html
SOURCE Amgen